Myeloid-derived suppressor cells: new insights into the pathogenesis and therapy of mds

HIGHLIGHTS

• who: Maria Velegraki et al. from the Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center-James, Columbus, OH, USA have published the research: Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS, in the Journal: (JOURNAL)
• what: Unfortunately, the trial was prematurely terminated during the dosing escalation phase before reaching the planned maximum dose, as there were no observed hematological responses in other than one patient, who showed a noteworthy increase in their hemoglobin levels . The main reason for the failure of this trial seems to be . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.